Product Description
Dovitinib is a pan-tyrosine kinase inhibitor targeting fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR) and other receptor tyrosine kinases (RTKs). Allarity exclusively in-licensed it (globally) from Novartis, who had completed a Phase 3 study in renal cell carcinoma (RCC) in addition to several promising Phase 2 studies in breast, liver and endometrial cancer and GIST. (Sourced from: https://allarity.com/pipeline/dovitinib/)
Mechanisms of Action: RTK Inhibitor,FGFR Inhibitor,VEGF Inhibitor,KITl Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Renal Cell Carcinoma|Oncology Solid Tumor Unspecified
Phase 2: Multiple Myeloma|Pancreatic Cancer|Glucagonoma|Insulinoma|Transitional Cell Carcinoma|Breast Cancer|Adenoid Cystic Carcinoma|Colorectal Cancer|Paraganglioma|Pheochromocytoma|Islet Cell Adenoma|Somatostatinoma|Neuroendocrine Tumors|Gastrointestinal Cancer|Gastrinoma|Bladder Cancer|Neuroendocrine Carcinoma|Islet Cell Carcinoma|Gastrointestinal Stromal Tumors|Endometrial Cancer|Hepatocellular Carcinoma|von Hippel-Lindau Disease|Prostate Cancer|Linitis Plastica|Gliosarcoma|Mesothelioma|Non-Small-Cell Lung Cancer|Glioblastoma|Renal Cell Carcinoma|Stomach Diseases|Salivary Gland Cancer|Scirrhous Adenocarcinoma|Brain Cancer|Head and Neck Cancer|Ovarian Cancer|Thyroid Cancer|Melanoma|Acute Myeloid Leukemia|Small Cell Lung Cancer|Adrenocortical Carcinoma|Male Breast Cancer|Inflammatory Breast Cancer|Oncology Unspecified|Kidney Cancer|Oncology Solid Tumor Unspecified
Phase 1: Renal Cell Carcinoma|Glioblastoma|Oncology Solid Tumor Unspecified|Breast Cancer|Kidney Cancer|Non-Small-Cell Lung Cancer|Acute Myeloid Leukemia|Multiple Myeloma|Adenocarcinoma|Diarrhea|Pancreatic Cancer|Neutropenia|Gastrointestinal Stromal Tumors|Thrombocytopenia|Bladder Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| AL-2003 | P1 |
Suspended |
Diarrhea|Neutropenia|Thrombocytopenia |
2024-10-01 |
|
| OPTIMISE-C19 | N/A |
Not yet recruiting |
COVID-19 |
2020-11-25 |
|
| NCI-2011-01106 | P2 |
Completed |
Prostate Cancer |
2017-06-12 |
|
| NCI-2014-00887 | P2 |
Terminated |
Prostate Cancer |
2017-06-05 |